In a multicenter Phase 2 trial, Ensatinib was used to treat ALK‐positive NSCLC patients whose disease had progressed after crizotinib treatment. Patients with TP53 mutations had significantly shorter PFS compared to patients with TP53 wild type (TP53 mutant group: 4.2 months compared to 11.7 months in the TP53 wild group) [24]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.